---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010379"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:03:23.956028+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q3 net loss narrows to $1.98M; paridiprubart study positive

## Summary
- Net loss $1.98M ($0.10/sh) vs $5.79M ($0.37/sh) YoY; nine-month loss $6.65M ($0.34/sh) vs $14.74M ($1.04/sh).
- Operating expenses fell to $2.06M from $5.80M in Q3; R&D down $3.52M to $1.03M due to lower clinical and manufacturing costs.
- Cash $6.46M, working capital $5.39M at June 30, 2023; raised $4.63M YTD from share/warrant sales.
- Positive university study data for paridiprubart (EB05) against respiratory pathogens; Phase 3 ARDS study ongoing.
- Completed Phase 2b dermatitis study with favorable topline; planning vitiligo Phase 2 and systemic sclerosis Phase 2 studies.

## SEC filing metadata
- accession: 0001654954-23-010379
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495423010379/0001654954-23-010379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495423010379/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010379
- JSON: https://secwatch.observer/filing/0001654954-23-010379.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.